Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

837.01 +14.50 (+1.76%)
Official Closing Price Updated: 7:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,790,560
Open 821.72
Bid (Size) 836.20 (1)
Ask (Size) 840.00 (1)
Prev. Close 822.51
Today's Range 819.50 - 842.13
52wk Range 711.40 - 972.53
Shares Outstanding N/A
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Market-Beating Stocks to Target This Week
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat

Performance

YTD
+7.6%
+7.6%
1 Month
-2.4%
-2.4%
3 Month
+9.5%
+9.5%
6 Month
-7.5%
-7.5%
1 Year
+8.3%
+8.3%

More News

Read More
Why Hims & Hers Stock Popped on Monday
Via The Motley Fool
This Is What Whales Are Betting On Eli Lilly
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Via The Motley Fool
Top 10 High Alpha Stocks For Dividend Investors
Via Talk Markets
Topics Stocks / Equities
Top gainers and losers in the S&P500 index during Friday's after-hours session.
Via Chartmill
What's going on in today's after hours session
Via Chartmill
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
Via Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Via Benzinga
3 Healthcare Stocks with Exciting Potential
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'
Via Benzinga
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock
Via The Motley Fool
3 Reasons to Sell ELAN and 1 Stock to Buy Instead
Via StockStory
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
Via Benzinga
On Sale Now: 20 Blue Chip Stocks to Buy
Via The Motley Fool
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Injects $1 Billion To Expand Vaccine Production In US
Via Benzinga
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Via Benzinga

Frequently Asked Questions

Is Eli Lilly publicly traded?
Yes, Eli Lilly is publicly traded.
What exchange does Eli Lilly trade on?
Eli Lilly trades on the New York Stock Exchange
What is the ticker symbol for Eli Lilly?
The ticker symbol for Eli Lilly is LLY on the New York Stock Exchange
What is the current price of Eli Lilly?
The current price of Eli Lilly is 837.01
When was Eli Lilly last traded?
The last trade of Eli Lilly was at 03/19/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.